Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
538964 Stock Overview
Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in Asia, Africa, the United States, the United Kingdom, and internationally.
Mercury Laboratories Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹501.25 |
52 Week High | ₹827.50 |
52 Week Low | ₹440.00 |
Beta | 0.34 |
1 Month Change | 0.25% |
3 Month Change | -15.45% |
1 Year Change | -32.51% |
3 Year Change | 80.63% |
5 Year Change | 15.90% |
Change since IPO | 1,442.78% |
Recent News & Updates
Shareholder Returns
538964 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 0.3% | 1.5% | 0.7% |
1Y | -32.5% | -10.4% | 10.6% |
Return vs Industry: 538964 underperformed the Indian Pharmaceuticals industry which returned -10.4% over the past year.
Return vs Market: 538964 underperformed the Indian Market which returned 10.6% over the past year.
Price Volatility
538964 volatility | |
---|---|
538964 Average Weekly Movement | 8.9% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 7.2% |
10% most volatile stocks in IN Market | 10.0% |
10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: 538964 is more volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 538964's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1962 | 660 | Rajendra Shah | https://www.mercurylabs.com |
Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in Asia, Africa, the United States, the United Kingdom, and internationally. It offers products in various segments, such as gynec, pediatric, surgeon, and physician. The company exports its formulations, such as anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cold and cough, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations.
Mercury Laboratories Fundamentals Summary
538964 fundamental statistics | |
---|---|
Market Cap | ₹601.50m |
Earnings (TTM) | ₹34.17m |
Revenue (TTM) | ₹623.73m |
17.6x
P/E Ratio1.0x
P/S RatioIs 538964 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
538964 income statement (TTM) | |
---|---|
Revenue | ₹623.73m |
Cost of Revenue | ₹271.05m |
Gross Profit | ₹352.68m |
Other Expenses | ₹318.51m |
Earnings | ₹34.17m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 28.48 |
Gross Margin | 56.54% |
Net Profit Margin | 5.48% |
Debt/Equity Ratio | 17.0% |
How did 538964 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield7%
Payout RatioValuation
Is Mercury Laboratories undervalued compared to its fair value and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
38.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 538964 (₹501.25) is trading below our estimate of fair value (₹813.19)
Significantly Below Fair Value: 538964 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 538964 is good value based on its PE Ratio (17.6x) compared to the Indian Pharmaceuticals industry average (21.4x).
PE vs Market: 538964 is good value based on its PE Ratio (17.6x) compared to the Indian market (20.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 538964's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 538964 is good value based on its PB Ratio (1.5x) compared to the IN Pharmaceuticals industry average (2.6x).
Future Growth
How is Mercury Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
21.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mercury Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Mercury Laboratories performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
18.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 538964 has high quality earnings.
Growing Profit Margin: 538964's current net profit margins (5.5%) are lower than last year (6.9%).
Past Earnings Growth Analysis
Earnings Trend: 538964's earnings have grown by 18.6% per year over the past 5 years.
Accelerating Growth: 538964's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 538964 had negative earnings growth (-20.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).
Return on Equity
High ROE: 538964's Return on Equity (8.7%) is considered low.
Financial Health
How is Mercury Laboratories's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 538964's short term assets (₹366.8M) exceed its short term liabilities (₹153.6M).
Long Term Liabilities: 538964's short term assets (₹366.8M) exceed its long term liabilities (₹101.8M).
Debt to Equity History and Analysis
Debt Level: 538964 has more cash than its total debt.
Reducing Debt: 538964's debt to equity ratio has reduced from 33.8% to 17% over the past 5 years.
Debt Coverage: 538964's debt is well covered by operating cash flow (116.3%).
Interest Coverage: 538964's interest payments on its debt are well covered by EBIT (85.9x coverage).
Balance Sheet
Dividend
What is Mercury Laboratories's current dividend yield, its reliability and sustainability?
Dividend Score
2/6Dividend Score 2/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.80%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 538964's dividend (0.8%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).
High Dividend: 538964's dividend (0.8%) is low compared to the top 25% of dividend payers in the Indian market (1.58%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 538964 has been paying a dividend for less than 10 years.
Growing Dividend: 538964's dividend payments have increased, but the company has only paid a dividend for 7 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (7%), 538964's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (11.7%), 538964's dividend payments are thoroughly covered by cash flows.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.4yrs
Average board tenure
CEO
Rajendra Shah (69 yo)
no data
Tenure
₹1,755,099
Compensation
Mr. Rajendra Ramanlal Shah has been the Managing Director of Mercury Laboratories Limited since March 31, 1992 and serves as its Chief Executive Officer and served as its Chairman of the Board until Februa...
CEO Compensation Analysis
Compensation vs Market: Rajendra's total compensation ($USD22.66K) is below average for companies of similar size in the Indian market ($USD38.54K).
Compensation vs Earnings: Rajendra's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: 538964's board of directors are considered experienced (7.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Mercury Laboratories Limited's employee growth, exchange listings and data sources
Key Information
- Name: Mercury Laboratories Limited
- Ticker: 538964
- Exchange: BSE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹601.500m
- Shares outstanding: 1.20m
- Website: https://www.mercurylabs.com
Number of Employees
Location
- Mercury Laboratories Limited
- 2/13-14, Gorwa Industrial Estate
- Gorwa Road
- Vadodara
- Gujarat
- 390016
- India
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/18 00:00 |
End of Day Share Price | 2022/05/18 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.